Today: 1 July 2026
Browse Category

NYSE:PFE 22 June 2025 - 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell, however, Wall Street had staged a dramatic recovery: Contrary to midday reports that the S&P 500 and Nasdaq 100 were modestly negative due to a risk‑off mood nasdaq.com, late‑day buying pushed all major indices into positive territory. Market breadth improved: the S&P 500 recorded 37 new 52‑week highs versus 7 lows, while the Nasdaq tallied 111 highs and 68 lows reuters.com.
1 October 2025
·····
Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

U.S. stock markets closed Sept. 30 higher, ending the month on a positive note. The S&P 500 closed at 6,688.46, the Dow at 46,397.89, and the Nasdaq at 22,660.01 reuters.com. All three indices notched monthly and quarterly gains: for September, the S&P rose about 3.5% reuters.com reuters.com, and the Dow and Nasdaq each notched their largest one-month rise since 2019. This pushed the Dow to another record closing high reuters.com. Defensive sectors outperformed, while cyclical areas lagged due to shutdown risks. On Wednesday, Oct. 1, U.S. markets opened in the red. In pre-market futures, the Dow e-mini futures were down roughly 0.66%, and S&P and Nasdaq futures fell about 0.8–0.9% reuters.com, as traders mulled the government shutdown and the delayed release of key data. Early trading globally was choppy: European stocks were modestly higher reuters.com, but Asia was mixed reuters.com. U.S. Treasuries and the dollar showed safe-haven flows while gold held at record highs reuters.com.
1 October 2025
··
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

“TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow patients to pay out-of-pocket for certain drugs, bypassing insurers and middlemen wbtv.com reuters.com. White House Press Secretary Karoline Leavitt confirmed on social media that Trump will announce TrumpRx, and a Wall Street Journal report says the site will be branded TrumpRx newsweek.com reuters.com. It is not yet clear which medications will be offered, but the idea is to force prices lower by having the government bulk-buy like a pharmacy. In effect, TrumpRx revives a concept from his first term but goes further by having the government directly sell drugs. Pharma experts note this is unprecedented: the government historically regulates prices or insurance reimbursement, not sell medicine directly. If implemented, TrumpRx would compete with private pharmacy programs. For example, in recent weeks Novartis, Novo Nordisk and other companies have launched their own direct-to-patient sales sites offering deep discounts on select drugs ktvz.com reuters.com. TrumpRx aims to join or even undercut those by using federal buying power. A White House official told Reuters that Pfizer will even sell some
30 September 2025
·
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector. Its trailing P/E is 12.64× reuters.com and forward P/E ~7.7× reuters.com, compared to ~19× for J&J and ~12× for Merck. Pfizer’s dividend yield reuters.com is by far the highest in big pharma. The stock rallied on strong earnings in early August s206.q4cdn.com reuters.com and on the Sept 30 Trump pricing news. Pfizer reported Q2 2025 revenue $14.7 billion s206.q4cdn.com and adjusted EPS $0.78, well above consensus. The company reaffirmed 2025 revenue guidance and raised EPS guidance by $0.10 to $2.90–3.10 s206.q4cdn.com, absorbing a one-time charge from the 3SBio deal. CEO Albert Bourla commented Pfizer had “another strong quarter of focused execution” s206.q4cdn.com, and CFO David Denton said robust results justified the higher guidance s206.q4cdn.com. Pfizer also highlighted cost savings from its turnaround program.
30 September 2025
··
Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Key Facts: After charging to all-time highs on Monday, U.S. tech stocks hit some turbulence to end the week. The Nasdaq Composite Index gained +0.44% on Friday to close around 22,484 reuters.com, helped by a relief rally on in-line inflation data. That advance broke a three-day losing streak for stocks latimes.com. Even so, the Nasdaq Composite fell ~0.7% for the week, while the S&P 500 and Dow also logged modest weekly declines reuters.com reuters.com. This marked the end of a three-week run of gains for the Nasdaq and S&P reuters.com. The Nasdaq-100 index of top-tier tech shares showed a similar pattern – rebounding Friday but finishing slightly lower week-over-week.
27 September 2025
··········
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s stock has struggled in 2025, hovering near multi-year lows. At ~$23.60 per share in late September, PFE has declined about 9% since January, underperforming the S&P 500 and lagging the broader healthcare sector. Over the past 12 months, the stock is down roughly 18%. The 52-week high was $30.43, and shares now sit not far above their year’s low of $20.92 stockanalysis.com. By market capitalization, Pfizer remains one of the world’s largest pharmaceutical companies, but its valuation has compressed significantly from pandemic-era peaks. This underperformance stems largely from the post-pandemic “hangover.” Pfizer’s once record-breaking COVID-19 product sales have dropped sharply, creating a tough comparison and denting investor sentiment. In 2022, Pfizer’s COVID vaccine and antiviral pill brought in a combined $37.8 billion in revenue; by 2024 that fell to $12.5 billion. Wall Street expects Pfizer’s total earnings per share to have more than halved from $6.58 in 2022 to about $3.05 in 2025. This “COVID cliff” and concerns over upcoming patent expirations have weighed heavily on the stock’s performance.
26 September 2025
···
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Sources: Key information and quotes in this report are sourced from recent Reuters news dispatches, official press releases, and expert commentary in credible outlets. For full details and further reading, please see the linked sources reuters.com reuters.com reuters.com reuters.com abcnews.go.com abcnews.go.com reuters.com reuters.com sciencedaily.com sciencedaily.com fiercehealthcare.com techstartups.com, among others. Each link corresponds to the original announcement or publication reporting the development in question. This roundup captures the major biotech, pharmaceutical, medical, and health news from August 17–18, 2025, highlighting the continuing innovations and challenges in the health sciences world. Let’s stay tuned as these stories evolve.
18 August 2025
·····
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

For the period August 16–17, 2025, the biotech, pharma, medical, and health sectors saw a range of significant developments worldwide. Below is a comprehensive roundup of top stories categorized by theme, complete with expert insights and source links: Each news item above includes direct source references for verification. This roundup spans clinical trial outcomes, drug approvals, industry deals, public health alerts, research breakthroughs, and policy updates from around the globe during August 16–17, 2025, keeping you up to date on the latest developments in the biotech, pharma, medical, and health sectors reuters.com ts2.tech. All signs indicate that the pace of innovation and change in healthcare remains as brisk as ever – from lab discoveries and regulatory milestones to boardroom shakeups and public health challenges – ensuring plenty more to watch in the weeks ahead.
17 August 2025
······
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

For the period August 15–16, 2025, the biotech, pharma, medical, and health sectors saw a flurry of significant developments worldwide. Here is a comprehensive roundup of the top stories, categorized by theme and featuring expert insights and source links: Novo Nordisk’s blockbuster weight-loss drug Wegovy received accelerated approval from the U.S. FDA to treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease reuters.com. This makes Wegovy the first GLP-1 class therapy cleared for MASH, an ailment affecting roughly 5% of U.S. adults reuters.com. The decision was based on part 1 of an ongoing trial showing Wegovy improved liver health and scarring in more patients than placebo reuters.com. “There really [have] not been good treatments in this space… we really need better medications that… prevent the progression of the disease,” said Jason Brett, Novo Nordisk’s U.S. medical chief reuters.com. Novo is pursuing approvals in Europe and Japan based on these interim results reuters.com, potentially strengthening its lead in metabolic diseases. Rival Eli Lilly’s tirzepatide has also shown promise in MASH in mid-stage trials reuters.com, underscoring the high-stakes race in this therapeutic area.
16 August 2025
··········
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

This weekend brought a flurry of significant biotech, pharmaceutical, medical, and health developments worldwide – from game-changing scientific breakthroughs to high-stakes regulatory decisions and industry shake-ups. Below is a comprehensive roundup of the major news from August 9 and 10, 2025, organized by category for easy reading. Sources: The information above is drawn from reputable sources including Reuters news reports reuters.com reuters.com, official WHO statements ts2.tech, and industry trade outlets like FiercePharma and FierceBiotech ts2.tech ts2.tech. Key developments are hyperlinked to their original sources for readers who wish to delve deeper into each story. All content has been fact-checked for accuracy and presented in an accessible manner for a general audience, with expert quotes included where available to provide additional insight.
10 August 2025
······
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Biotechnology is at the forefront of scientific innovation in 2025, driven by companies around the world that are transforming healthcare, agriculture, and industry. This report profiles 100 of the most important global biotechnology companies selected for their global impact, innovation, revenue, scientific breakthroughs, and sector influence. These companies span biopharmaceutical giants, genomics and diagnostics pioneers, agricultural and environmental biotech leaders, industrial biotech innovators, and key providers of biotech tools and services. Each entry includes the company’s headquarters country, primary sector, notable contributions or innovations, and a link to its official website. The list encompasses both publicly traded and private firms, reflecting the worldwide landscape of biotech innovation. Selection Criteria: Companies were chosen based on their demonstrated leadership or innovation in their field, significant contributions to science and health, financial strength, and influence within their sector. The selection emphasizes current industry positioning and breakthroughs – from life-saving vaccines and therapies to cutting-edge genomic technologies and sustainable biological solutions.
22 June 2025
···········
1 … 9 10 11

Stock Market Today

  • Bending Spoons (AOL) Jumps 41% After $1.7B Nasdaq IPO
    July 1, 2026, 3:50 PM EDT. Bending Spoons, which owns AOL plus holdings like Eventbrite and Vimeo, raised $1.7 billion in a Nasdaq IPO Wednesday. The tech investor, based in Italy, priced 58 million shares at $29. It drew in $1 billion for the company and the rest went to selling shareholders. The stock jumped 41% at the open, pushing Bending Spoons' value to $25.5 billion. Started in 2013, the firm buys up troubled tech names and uses AI to revive them. Bending Spoons posted $601 million revenue in Q1 2026 and $27.5 million net, with $4.4 billion in debt. The new cash is marked for more deals as the IPO window reopens after SpaceX's listing.
Go toTop